Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

INTEGRATED MICROFLUIDIC PLATFORM FOR PROTEOMIC AND GENETIC EXOSOME DETECTION

Project description

An exosome detection platform for cancer diagnosis

Liquid biopsy is a non-invasive approach for personalised cancer diagnosis and relies on circulating tumour cells and tumour DNA. However, extracellular vesicles termed exosomes are emerging as promising biomarkers for prompt cancer detection. To facilitate routine exosome analysis in the clinic, scientists of the EU-funded IMPED project propose to develop a next-generation technology capable of extracting and analysing exosomes from liquid biopsies or serum samples at the proteomic and genomic levels. The technology will be the first to combine both intra- and extra-vesicle detection on a single platform, offering important insight into precision cancer management on an individual patient basis.

Objective

In order to adapt treatment to the multicity of cancer types, cancer patient management has been revolutionized in the past decades by personalized medicine. As part of this strategy, liquid biopsy has emerged as a non-invasive approach for personalized diagnostics and treatment. So far, this approach has focused on circulating tumor cells and circulating tumor DNA. However, extracellular vesicles termed exosomes, which are implicated in cellular communication and molecule transfer, have risen as promising biomarkers for earlier and more accurate detection. The IMPED project aims at developing a next-generation technology able to extract and analyse single exosomes or sub-groups of exosomes on both the proteomic and genomic level. This platform will offer beyond state-of-the-art information on the involvement of exosomes in cancer development. It has the potential to increase the precision of liquid biopsy analysis and provide clinically relevant insight for personalized cancer management. Toward this goal, the IMPED project will gather three technologies allowing low-cost extraction and analysis of exosomes from human plasma: (1) Continuous label-free extraction of exosomes from complex matrices (plasma) using thermophoresis (2) Proteomic profiling of single exosomes immobilized on a nanoarray with possibility of release (3) Droplet-based reverse transcriptase polymerase chain reaction (RT-PCR) of exosomes for RNA content analysis To our knowledge, this would be the first technology to couple intra- and extra-vesicle detection on a single/subpopulation exosome level within a single platform. The IMPED project is interdisciplinary, connecting physics, microfluidics and bioassay development for biomedical applications.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2019

See all projects funded under this call

Coordinator

INSTITUT CURIE
Net EU contribution
€ 225 381,36
Address
RUE D ULM 26
75231 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
€ 225 381,36

Partners (1)